Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing

Novo Ventures, the ventures arm of Novo Holdings, today announces that its portfolio company, F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, has secured US $60.8 million in new financing from new and existing investors. Naveed Siddiqi Partner at Novo Ventures, joins the F2G Board, replacing Martin Edwards who is retiring.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...